drugset / Trial / NCT00138983

Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.

NCT00138983 ↗

RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to determine wich treatment is the most effective in prevention of glucocorticoid-induced osteoporosis in patients with rheumatic diseases. The STOP-study: a randomized placebo controlled trial with alendronate versus alfacalcidol.

Timeline

Start
2000-05
Primary completion
—
Completion
2003-11

Outcome

Met primary endpoint

paper At 18 months, the mean difference of change in bone mineral density between the two groups was 4.0 percent (95 percent confidence interval, 2.4 to 5.5 percent). PMID 16914703 ↗

paper alendronate was more effective in the prevention of glucocorticoid-induced bone loss than was alfacalcidol. PMID 16914703 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Alendronic Acid Small molecule 10 mg —
Subject Alfacalcidol Other / unclassified 1 ug —